Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

63 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of aflibercept plus FOLFIRI and potential efficacy biomarkers in patients with metastatic colorectal cancer: the POLAF trial.
Élez E, Gómez-España MA, Grávalos C, García-Alfonso P, Ortiz-Morales MJ, Losa F, Díaz IA, Graña B, Toledano-Fonseca M, Valladares-Ayerbes M, Polo E, Salgado M, Martínez de Castro E, Safont MJ, Salud A, Ruiz-Casado A, Tabernero J, Riesco MDC, Rodriguez-Ariza A, Aranda E. Élez E, et al. Among authors: safont mj. Br J Cancer. 2022 Apr;126(6):874-880. doi: 10.1038/s41416-021-01638-w. Epub 2021 Dec 22. Br J Cancer. 2022. PMID: 34937947 Free PMC article. Clinical Trial.
Retrospective study of efficacy and toxicity on patients older than 70 years within a randomized clinical trial of two cisplatin-based combinations in patients with small-cell lung cancer.
Safont MJ, Artal-Cortes A, Sirera R, Gómez-Codina J, González-Larriba JL, Barneto I, Carrato A, Isla D, Rosell R, Camps C. Safont MJ, et al. Lung Cancer. 2009 Jan;63(1):83-7. doi: 10.1016/j.lungcan.2008.04.015. Epub 2008 Jun 13. Lung Cancer. 2009. PMID: 18555556 Clinical Trial.
Addition of bevacizumab to XELOX induction therapy plus concomitant capecitabine-based chemoradiotherapy in magnetic resonance imaging-defined poor-prognosis locally advanced rectal cancer: the AVACROSS study.
Nogué M, Salud A, Vicente P, Arriví A, Roca JM, Losa F, Ponce J, Safont MJ, Guasch I, Moreno I, Ruiz A, Pericay C; AVACROSS Study Group. Nogué M, et al. Among authors: safont mj. Oncologist. 2011;16(5):614-20. doi: 10.1634/theoncologist.2010-0285. Epub 2011 Apr 5. Oncologist. 2011. PMID: 21467148 Free PMC article. Clinical Trial.
Preoperative chemotherapy in patients with intermediate-risk rectal adenocarcinoma selected by high-resolution magnetic resonance imaging: the GEMCAD 0801 Phase II Multicenter Trial.
Fernandez-Martos C, Brown G, Estevan R, Salud A, Montagut C, Maurel J, Safont MJ, Aparicio J, Feliu J, Vera R, Alonso V, Gallego J, Martin M, Pera M, Sierra E, Serra J, Delgado S, Roig JV, Santos J, Pericay C. Fernandez-Martos C, et al. Among authors: safont mj. Oncologist. 2014 Oct;19(10):1042-3. doi: 10.1634/theoncologist.2014-0233. Epub 2014 Sep 10. Oncologist. 2014. PMID: 25209376 Free PMC article. Clinical Trial.
Neoadjuvant and conversion treatment of patients with colorectal liver metastasis: the potential role of bevacizumab and other antiangiogenic agents.
García-Alfonso P, Ferrer A, Gil S, Dueñas R, Pérez MT, Molina R, Capdevila J, Safont MJ, Castañón C, Cano JM, Lara R. García-Alfonso P, et al. Among authors: safont mj. Target Oncol. 2015 Dec;10(4):453-65. doi: 10.1007/s11523-015-0362-0. Epub 2015 Mar 11. Target Oncol. 2015. PMID: 25752908 Free PMC article. Review.
A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: clinical and biological features.
Salazar R, Capdevila J, Laquente B, Manzano JL, Pericay C, Villacampa MM, López C, Losa F, Safont MJ, Gómez A, Alonso V, Escudero P, Gallego J, Sastre J, Grávalos C, Biondo S, Palacios A, Aranda E. Salazar R, et al. Among authors: safont mj. BMC Cancer. 2015 Feb 26;15:60. doi: 10.1186/s12885-015-1053-z. BMC Cancer. 2015. PMID: 25886378 Free PMC article. Clinical Trial.
Randomized trial of TAS-102 for refractory metastatic colorectal cancer.
Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N, Yamazaki K, Shimada Y, Tabernero J, Komatsu Y, Sobrero A, Boucher E, Peeters M, Tran B, Lenz HJ, Zaniboni A, Hochster H, Cleary JM, Prenen H, Benedetti F, Mizuguchi H, Makris L, Ito M, Ohtsu A; RECOURSE Study Group. Mayer RJ, et al. N Engl J Med. 2015 May 14;372(20):1909-19. doi: 10.1056/NEJMoa1414325. N Engl J Med. 2015. PMID: 25970050 Free article. Clinical Trial.
First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD).
Carrato A, Abad A, Massuti B, Grávalos C, Escudero P, Longo-Muñoz F, Manzano JL, Gómez A, Safont MJ, Gallego J, García-Paredes B, Pericay C, Dueñas R, Rivera F, Losa F, Valladares-Ayerbes M, González E, Aranda E; Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD). Carrato A, et al. Among authors: safont mj. Eur J Cancer. 2017 Aug;81:191-202. doi: 10.1016/j.ejca.2017.04.024. Epub 2017 Jun 19. Eur J Cancer. 2017. PMID: 28633089 Free article. Clinical Trial.
A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients.
Elez E, Pericay C, Valladares-Ayerbes M, Bando I, Safont MJ, Gallego J, Grávalos C, Arrivi A, Carrato A, Conde V, Ortiz MJ, López C, Alonso B, Ruiz de Mena I, Díaz-Rubio E, Tabernero J, Aranda E. Elez E, et al. Among authors: safont mj. Br J Cancer. 2019 Aug;121(5):378-383. doi: 10.1038/s41416-019-0537-z. Epub 2019 Jul 31. Br J Cancer. 2019. PMID: 31363167 Free PMC article. Clinical Trial.
Tumour location and efficacy of first-line EGFR inhibitors in KRAS/RAS wild-type metastatic colorectal cancer: retrospective analyses of two phase II randomised Spanish TTD trials.
Benavides M, Díaz-Rubio E, Carrato A, Abad A, Guillén C, Garcia-Alfonso P, Gil S, Cano MT, Safont MJ, Gravalos C, Manzano JL, Sánchez A, Alcaide J, López R, Massutí B, Sastre J, Martínez E, Escudero P, Méndez M, Aranda E. Benavides M, et al. Among authors: safont mj. ESMO Open. 2019 Dec 1;4(6):e000599. doi: 10.1136/esmoopen-2019-000599. eCollection 2019. ESMO Open. 2019. PMID: 31803504 Free PMC article. Clinical Trial.
63 results